http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Pathophysiology, Evaluation and Management
XVI, 525 p. 127 illus., 101 illus. in color. online resource.
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program’s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.